Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

427 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) trial: study protocol for a multicentre, double-blinded, placebo-controlled, phase IIa trial.
Mullish BH, Innes AJ, Roberts LA, Anim-Burton S, Webber L, Johnson NA, Ghani R, Farshi P, Khan AB, Kinsella F, Kottaridis P, Krishnamurthy P, Nicholson E, Palanicawandar R, Wheeler G, Davies F, Marchesi JR, Pavlů J. Mullish BH, et al. Among authors: krishnamurthy p. BMJ Open. 2024 Dec 22;14(12):e093120. doi: 10.1136/bmjopen-2024-093120. BMJ Open. 2024. PMID: 39773995 Clinical Trial.
Quantifying and mitigating motor phenotypes induced by antisense oligonucleotides in the central nervous system.
Moazami MP, Rembetsy-Brown JM, Sarli SL, McEachern HR, Wang F, Ohara M, Wagh A, Kelly K, Krishnamurthy PM, Weiss A, Marosfoi M, King RM, Motwani M, Gray-Edwards H, Fitzgerald KA, Brown RH, Watts JK. Moazami MP, et al. Among authors: krishnamurthy pm. Mol Ther. 2024 Dec 4;32(12):4401-4417. doi: 10.1016/j.ymthe.2024.10.024. Epub 2024 Oct 28. Mol Ther. 2024. PMID: 39460376 Free PMC article.
CASCADES, a novel SOX2 super-enhancer-associated long noncoding RNA, regulates cancer stem cell specification and differentiation in glioblastoma.
Shahzad U, Nikolopoulos M, Li C, Johnston M, Wang JJ, Sabha N, Varn FS, Riemenschneider A, Krumholtz S, Krishnamurthy PM, Smith CA, Karamchandani J, Watts JK, Verhaak RGW, Gallo M, Rutka JT, Das S. Shahzad U, et al. Among authors: krishnamurthy pm. Mol Oncol. 2024 Sep 25. doi: 10.1002/1878-0261.13735. Online ahead of print. Mol Oncol. 2024. PMID: 39323013 Free article.
Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapy.
Othman J, Hwang A, Brodermann M, Abdallah I, McCloskey K, Gallipoli P, Clarke G, Dang R, Vidler J, Krishnamurthy P, Basheer F, Latif AL, Palanicawandar R, Taylor T, Khan A, Campbell V, Hogan F, Kanellopoulos A, Fleming K, Collins A, Dalley C, Loke J, Marshall S, Taussig D, Munisamy S, Loizou E, Yassin H, Dennis M, Zhao R, Belsham E, Murray D, Fowler N, O'Nions J, Khan A, Sellar R, Dillon R. Othman J, et al. Among authors: krishnamurthy p. Blood Adv. 2024 Nov 12;8(21):5590-5597. doi: 10.1182/bloodadvances.2024014017. Blood Adv. 2024. PMID: 39265176 Free PMC article.
Translational Challenges in Cancer Nanotherapy.
Ravi Kiran AVVV, Kusuma Kumari G, Krishnamurthy PT, Kalyan Chekreverthy B. Ravi Kiran AVVV, et al. Among authors: krishnamurthy pt. Adv Pharm Bull. 2024 Jul;14(2):253-254. doi: 10.34172/apb.2024.021. Epub 2023 Oct 25. Adv Pharm Bull. 2024. PMID: 39206393 Free PMC article. No abstract available.
427 results